# Prescription and Utilization of Low Molecular Weight Heparin in Usual Medical Practice for the Curative Treatment of Venous Thromboembolism in Patients With Cancer

> **NCT01803022** · — · COMPLETED · sponsor: **LEO Pharma** · enrollment: 419 (actual)

## Conditions studied

- Venous Thromboembolism

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT01803022
- **Lead sponsor:** LEO Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2012-11
- **Primary completion:** 2013-07
- **Final completion:** 2013-07
- **Target enrollment:** 419 (ACTUAL)
- **Last updated:** 2018-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01803022

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01803022, "Prescription and Utilization of Low Molecular Weight Heparin in Usual Medical Practice for the Curative Treatment of Venous Thromboembolism in Patients With Cancer". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT01803022. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*